Recruiting
Phase 1

IBI3042

Sponsor:

Fortvita Biologics (USA)Inc.

Code:

NCT07842393

Conditions

Healthy Volunteers (HV)

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Investigational Drug: IBI3042

Matching Placebo

Study Details

Brief summary:

This is a randomized, investigator- and participant-blinded, placebo-controlled, parallel-group, dose-escalation Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of IBI3042, in healthy adult participants. Approximately 32 healthy participants will be enrolled across 4 single ascending dose groups, with 8 participants per group randomized in a 6:2 ratio to receive a single oral dose of IBI3042 or matching placebo. A sentinel-dosing design is used for the first dose cohort. Safety and PK data are assessed to support dose escalation decisions by the Safety Review Committee.

Conditions

Healthy Volunteers (HV)

Study ID

NCT07842393

Start date

Oct 20, 2026

Status verified date

Nov, 2026

Completion date

Mar 2, 2027

Anticipated

Primary completion date

Mar 2, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Aged 18 to 55 years, inclusive.
  • BMI ≥20 and <32 kg/m² and body weight ≥50 kg;
  • Female participants of childbearing potential and male participants with female partners of childbearing potential must agree to use highly effective contraception during the study and for 90 days after the last dose.
  • Able and willing to comply with study procedures and voluntarily provide written informed consent.

Exclusion Criteria:

  • Known or suspected hypersensitivity to any component of the study drug or to GLP-1 receptor agonists.
  • History of diabetes or abnormal glycemic parameters at screening.
  • Personal or family history of thyroid C-cell carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2A or 2B), or calcitonin ≥20 ng/L at screening.
  • History of acute or chronic pancreatitis, or clinically significant pancreatic enzyme elevation at screening.
  • Use of medications that may significantly affect gastrointestinal motility, appetite, or drug absorption within 3 months prior to screening.
  • Clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease that may increase study-related risk or interfere with study assessments.
  • Clinically significant abnormalities in physical examination or laboratory tests at screening.
  • History of malignancy within 5 years, except for basal cell or squamous cell skin cancer.
  • Use of prescription or over-the-counter medications, or dietary supplement vitamins within 2 weeks or 5 half-lives, whichever is greater, prior to screening; or use of any herbal products within 4 weeks prior to screening.
  • Participation in another drug or medical device clinical study within 3 months prior to screening or within 5 half-lives of the investigational drug, as applicable.
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in the study.

Study Design

Enrollment

32 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Matching Placebo

Oral, matching to IBI3042, corresponding dose regimen according to study cohort

experimental: Investigational Drug: IBI3042

Oral, corresponding dose regimen according to study cohort

Interventions

Investigational Drug: IBI3042

Oral, corresponding dose regimen according to study cohort

Matching Placebo

Oral, matching to IBI3042, corresponding dose regimen according to study cohort

Primary outcome measure

  • Number of Participants With Adverse Events [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Clinically Significant Abnormal Vital Signs [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Clinically Significant Abnormal 12-lead electrocardiogram [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal General Appearance Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Respiratory Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Cardiovascular Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Abdominal Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Skin Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Head and Neck Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Lymph Node Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Thyroid Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Musculoskeletal Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Neurological Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Blood Routine Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Blood Biochemistry Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Coagulation Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Urine Routine Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Calcitonin Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Glycated Hemoglobin Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Infection-Related Immunology Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Thyroid Function Findings [ Time Frame: through study completion, an average of 29 days ]
  • Number of Participants With Abnormal Pregnancy Test Findings [ Time Frame: through study completion, an average of 29 days ]

Central Contacts and Locations

Locations

ICON Lenexa

Recruiting

Lenexa, Kansas, United States, 66219

Contacts

Principal Investigator:

Pactrick Yao, PhD

More Information

Sponsor

Fortvita Biologics (USA)Inc.

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Keywords

  • Glucagon-Like Peptide 1 Receptor Agonists
  • Healthy Volunteers
  • Phase 1 Clinical Trials
  • Pharmacokinetics
  • Safety

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Fortvita Biologics (USA)Inc. on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.